36. The use of any one of Claims 25-35, wherein the conjugate is to be administered at a dose of 5 to 200 μg/cm^3 of tumor, more particularly 10 to 150 μg/$cm^3$of tumor, and more particularly 15 to 100 μg/$cm^3$of tumor.

37. The use of any one of Claims 25-36, wherein the conjugate is to be administered in a single dose.

38. The use of any one of Claims 25-36, wherein the conjugate is to be administered in 2, 3, 4, 5, 6, 7, 8, 9, 10 doses, or more.

39. The use of Claim 38, wherein the doses are to be administered over a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days; or 1, 2, 3, 4, 5, or 6 weeks; or 1, 2, 3, 4, 5, or 6 months, or more.